Patents Assigned to Iovance Biotherapeutics
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11517592
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: December 6, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
    Patent number: 11433097
    Abstract: Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 6, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventor: Maria Fardis
  • Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
    Patent number: 11401507
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 2, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11384337
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Cecile Chartier-Courtaud, Krit Ritthipichai
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11369637
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: December 11, 2021
    Date of Patent: June 28, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11364266
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: December 11, 2021
    Date of Patent: June 21, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
    Patent number: 11357841
    Abstract: Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 14, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Krit Ritthipichai, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11351199
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: June 7, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11351198
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: June 7, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11344581
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: May 31, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11344579
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 31, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11344580
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 31, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11337998
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 24, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11311578
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: April 26, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11304980
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: April 19, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11304979
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: April 19, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
    Patent number: 11293009
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 5, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11291687
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: April 5, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11273181
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: March 15, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Patent number: 11273180
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: March 15, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze